Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial

Aditya H. Gaur, R. Kiplin Guy, John C. Panetta et al.|The Lancet Infectious Diseases|2020

Cited by 77